Key result
Ex vivo lentiviral gene transfer of RANTES 9-68 prolonged cardiac allograft survival to a median of 20 days compared to 15 days in controls.
Why the study?
Does ex vivo lentiviral gene transfer of RANTES 9-68 prolong heart graft survival in a rat allograft model?
Does ex vivo lentiviral gene transfer of RANTES 9-68 prolong heart graft survival in a rat allograft model?
Answers are grounded in this paper and cite their sources.
Ex vivo lentiviral gene transfer of the chemokine antagonist RANTES 9-68 significantly prolongs cardiac allograft survival in a rat model, suggesting a potential strategy for organ preservation.
BACKGROUND: Allograft tolerance might be achieved by expressing immunomodulatory proteins through gene therapy. We have evaluated the possibility of promoting significantly allograft survival in a vascularized cardiac allograft model by performing ex vivo gene transfer. We used a lentiviral vector encoding the chemokine antagonist RANTES 9-68 that is capable of competing with native RANTES. METHODS: The Fisher donor/Lewis recipient rat strain combinations were used and all animals received for the first 5 days posttransplantation a subtherapeutic dose of cyclosporine A (1.5 mg/kg). Ex vivo gene transfer into heart allograft was performed by multiple injections of the SIN.cPPT lentiviral vector, which corresponds to the multiply attenuated, self-inactivating lentivector derived from the human immunodeficiency virus (HIV)-1. RESULTS: About 6% of the cardiac tissue had integrated lentiviral vector, which closely matches the mean in vivo RANTES antagonist expression of 5% obtained by immunohistochemistry. In vivo RANTES 9-68 expression has significantly prolonged graft survival (median [25%-75%]: 20 [17-26] days), compared to the control 15 ([14-15] days; P=0.0007). Furthermore, hearts transduced with RANTES 9-68 showed a significant (P<0.05) reduction in cell infiltration and intragraft expression of TNF-alpha, IFN-gamma, endogenous RANTES, and TGF-beta. CONCLUSION: Lentiviral gene transfer of RANTES 9-68 antagonist attenuates significantly the inflammatory response and delays allograft rejection, despite low levels of transduction. Future improvement of heart transduction by lentiviral vectors, as it has been achieved with other vectors, might become an attractive alternative therapy for treating allografts that require sustained gene expression for better organ preservation.
No takes yet. Share an insight, caveat, or question.
Vassalli et al. (2006) studied Cardiac allograft rejection. Ex vivo gene transfer of lentiviral vector encoding RANTES 9-68 vs. Control was evaluated on Graft survival (median days) (p=0.0007). Ex vivo lentiviral gene transfer of RANTES 9-68 prolonged cardiac allograft survival to a median of 20 days compared to 15 days in controls.
Synapse has enriched 10 related papers. Consider them for comparative context: